The Enhanced Games — tech’s steroid extravaganza — didn’t pay off, as company posts $60 million loss

techcrunch.com Aug 20, 2026

The Enhanced Games — tech’s steroid extravaganza — didn’t pay off, as company posts $60 million loss

Curated by Shubham · TechCapsules · Aug 20, 2026

AI-summarised brief · reviewed before publication

The Enhanced Games, a Las Vegas‑hosted competition allowing athletes to use performance‑enhancing drugs, concluded in May with athletic achievement and a financial shortfall. Organized by Enhanced Group, a telehealth firm backed by Peter Thiel and staffed by crypto, AI and biotech veterans, the event produced only one world record in swimming and failed to generate the excitement. In its second‑quarter earnings released this week, Enhanced Group reported a net loss of nearly $62 million, largely attributed to the Games’ costs. Revenue for the quarter was $17.7 million, driven mainly by game‑related sponsorships rather than the company’s core FDA‑approved telehealth treatments. The firm hinted at a shift toward a lower‑cost online series, “Enhanced Breakers,” while the broader peptide market continues to expand amid regulatory uncertainty.

💡 Why It Matters

· The loss exposes the risk of betting on spectacle‑driven biotech ventures, forcing investors to reassess the viability of merging performance‑enhancement hype with consumer health platforms.

Biotechnology Capsules

Read full article on techcrunch.com

AI isn’t close to curing cancer. This startup says it knows what…

Biotech startup Vivodyne argues that AI drug discovery is hindered by a lack of causal biological data, relying instead on animal testing or single-cell studies. To address this, the company developed HIVE, modular robotic labs that autonomously grow and dose twenty types of human tissue. CEO Andrei Georgescu claims these systems generate the complex, living-tissue data current AI models lack, noting that existing models often only predict outcomes in mice. While industry leaders like Anthropic’s Dario Amodei and OpenAI’s Sam Altman have touted AI’s potential to cure cancer, actual results remain limited, with few AI-designed drugs advancing to late-stage trials. Vivodyne, spun out of the University of Pennsylvania, recently opened a large facility near San Francisco. The company reports high predictive accuracy for its liver, airway, and bone marrow tissues compared to human trials. Having raised nearly $80 million, Vivodyne aims to provide pharmaceutical partners with reliable human-relevant data before expensive clinical trials, potentially reducing the high failure rate of drugs that succeed in animal tests but fail in humans.

💡 Vivodyne challenges the industry’s reliance on static cellular snapshots by providing dynamic, causal data from living human tissues. This approach directly addresses the critical bottleneck where 90% of animal-effective drugs fail in human trials, offering a tangible path to validate AI predictions before costly clinical testing begins.

straitstimes.com · Aug 15

Forget silicon chip servers, Singapore’s newest data centre needs to be fed

Singapore’s National University of Science has launched the country’s first biological data centre, utilizing living human brain cells instead of traditional silicon chips. Developed by Australian biotech firm Cortical Labs in partnership with NUS and DayOne, the facility went live on July 16. Technicians maintain the system by feeding the neurons a nutrient cocktail and regulating gas levels every three days. The centre currently houses 20 biological computer units, each containing at least 200,000 lab-grown neurons derived from reprogrammed blood cells. These neurons exchange electrical signals with computers to generate raw computing power. Cortical Labs CEO Hon Weng Chong stated that this technology excels in scenarios with limited data, such as training humanoid robots for unpredictable environments or enhancing cybersecurity anomaly detection. The setup mirrors human learning capabilities, allowing efficient application of knowledge from few examples. Plans exist to expand the facility to 1,000 units pending regulatory approval. This initiative follows Cortical Labs’ commercialization of a similar system in Melbourne.

💡 This technology bypasses the massive data requirements of traditional AI, enabling robots to adapt to unpredictable real-world environments with minimal training. It offers a viable path for deploying autonomous systems where collecting vast datasets is impractical or impossible.

completeaitraining.com · Aug 15

AI virtual cells aim to speed drug testing by simulating cellular responses

Scientists are developing AI models to simulate human cellular responses to drugs and genetic changes, enabling computational testing before costly laboratory experiments. GenBio AI, a Palo Alto-based startup, is pioneering this technology with its AI-driven digital organism, the Artificial Intelligence-Driven Digital Organism (AIDO). This system connects biological information across multiple scales, from molecules to cells, allowing researchers to predict how interventions affect biological systems. Unlike narrower models focusing on single tasks, AIDO integrates data to simulate complex cellular processes. The company utilizes AI agents to autonomously build and refine these models, reducing manual work. While virtual cells will not replace physical experiments or clinical trials, they aim to streamline early-stage research by narrowing down viable drug candidates and hypotheses. This approach addresses significant technical challenges in integrating diverse biological data to improve prediction accuracy and efficiency in biomedical research.

💡 By shifting initial drug screening from wet labs to digital simulations, this technology drastically reduces the time and capital required to identify viable therapeutic candidates. It transforms early-stage discovery from a trial-and-error process into a predictive science, allowing researchers to eliminate ineffective compounds before they ever touch a petri dish.

thequantuminsider.com · Aug 13

Xanadu and University of Alberta Explore Quantum Computing for Cancer Drug Discovery

Xanadu Quantum Technologies and the University of Alberta have announced a strategic research partnership to develop quantum algorithms for designing photosensitizers used in photodynamic cancer therapy. The collaboration pairs Xanadu’s expertise in photonic quantum computing with Professor Alex Brown’s work on computational modeling of light‑matter interactions in photosensitizer systems. Researchers will create a quantum‑computing framework aimed at accelerating the discovery of compounds that activate under specific wavelengths to kill tumor cells, a process that classical simulations struggle to capture accurately. Xanadu recently demonstrated quantum simulations of key excited‑state properties, and Brown’s benchmark studies will guide algorithm development. The effort targets early fault‑tolerant quantum computers to overcome bottlenecks in drug‑design workflows. The partnership includes publications and access to Xanadu’s quantum platform.

💡 By tackling the notoriously hard excited‑state chemistry of photodynamic agents, the alliance could deliver a new class of precision oncology drugs that are faster and cheaper to develop.

en.sedaily.com · Aug 13

Korea Procurement Chief Visits AI Surgical Robot Firm Roen Surgical

Public Procurement Service Administrator Baek Seung-bo visited Roen Surgical, a Daejeon-based developer of AI surgical robots, on the 13th to inspect its facilities at KAIST’s Munji Campus. During the tour, Baek observed a demonstration of Zamenix, an AI-driven robotic system designed to precisely break and remove kidney stones using laser technology. The company, designated as a PPS innovation product in 2025, is currently undergoing field validation at the National Medical Center via a pilot purchase. Baek emphasized his administration’s commitment to supporting emerging industries like AI and robotics. He stated that the public sector will provide comprehensive assistance to help these advanced products utilize government procurement as a strategic springboard. This support aims to open new sales channels and foster growth for innovative technologies, positioning them as core drivers of future national competitiveness in the medical robotics sector.

💡 Government backing transforms experimental medical tech into viable commercial products by guaranteeing initial market access. This procurement strategy directly accelerates the domestic adoption of AI-driven surgical tools, bypassing traditional commercialization hurdles.

artificialintelligence-news.com · Aug 11

Novo Nordisk and AWS bring agentic AI into drug discovery

Novo Nordisk has designated AWS as its preferred cloud provider and strategic AI partner, expanding the use of artificial intelligence tools across its drug discovery processes. The collaboration includes establishing a co-innovation hub in London, where AWS engineers and Novo Nordisk scientists will jointly work on research data and insights. This partnership aims to integrate agentic AI into target identification, therapy design, and research workflows, reducing handoffs between computational analysis and laboratory research. AWS will provide access to Amazon Bio Discovery, offering over 40 biological AI models, and Amazon Bedrock AgentCore for deploying autonomous agents. The initiative builds on existing internal AI adoption, where generative AI has already streamlined clinical documentation. By combining AWS’s cloud infrastructure with Novo Nordisk’s scientific expertise in chronic diseases, the companies intend to shorten the timeline from identifying drug targets to achieving first human doses, linking computational design directly with physical testing.

💡 Integrating autonomous agents directly into the wet-lab feedback loop eliminates traditional silos between data science and experimental biology. This structural shift allows pharmaceutical researchers to iterate on drug candidates in real-time, potentially compressing years of development into months.